Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days in July 2025, indicating unusual trading activity [1] Company Operations - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the market environment or industry policies [1] - The company has conducted a self-examination and consulted with its controlling shareholder and actual controller, finding no undisclosed significant information [1] Investor Advisory - The company advises investors to be cautious of trading risks in the secondary market and to make rational decisions regarding their investments [1]

Group 1 - The market saw a total of 31 stocks hitting the daily limit up, with a success rate of 63% for limit up attempts [1] - Xizang Tourism became a market focus, achieving a consecutive limit up for 7 trading days, making it a representative high-limit stock [1] - Innovative drug concept stocks showed strong performance, with Apac Pharmaceutical achieving 5 limit ups in 10 trading days due to improved earnings expectations from a subsidiary sale [1] Group 2 - The overall market performance indicated a slight decline in the Shanghai Composite Index by 0.08% and Shenzhen Component Index by 0.04%, while the ChiNext Index rose by 0.92% [1] - The total trading volume in the three major markets reached 11,460.26 billion yuan, with 3,901 stocks declining and 1,468 stocks rising [1] - The chemical pharmaceutical sector attracted the highest net inflow of funds at 1.568 billion yuan, followed by the biopharmaceutical sector with 1.245 billion yuan [1] Group 3 - Other stocks that hit the limit up included Xingfu Blue Ocean, Kejingyuan, and Haichang New Materials, with some ChiNext stocks achieving a 20% limit up, indicating strong market enthusiasm for related concepts [2] - Medical research outsourcing institutions (CRO) and contract development manufacturing organizations (CDMO) were among the top-performing sectors, along with FPGA chips and CXO medical outsourcing [2]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][40]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 1.90% from July 21 to July 25, 2025, ranking 19th among 31 industries in the Shenwan index, outperforming the CSI 300 index by 0.21 percentage points [4][12]. - The current PE valuation of the pharmaceutical and biotechnology sector is 30.67 times, which is at the historical median level, with a valuation premium of 140% compared to the CSI 300 index [4][18]. - The top three performing sub-sectors during the same period were medical services (6.73%), medical devices (4.43%), and pharmaceutical commerce (1.84%) [4][12]. Market Performance - In the year-to-date, the pharmaceutical and biotechnology sector has increased by 18.81%, ranking 3rd among 31 industries, and outperforming the CSI 300 index by 13.92 percentage points [4][13]. - The sub-sectors that achieved significant gains include chemical pharmaceuticals (34.25%), medical services (32.34%), and biological products (13.49%) [4][19]. Industry News - The National Healthcare Security Administration (NHSA) held two meetings to support the high-quality development of innovative drugs and medical devices, emphasizing the need for comprehensive value assessments for innovative products [5][34]. - The NHSA introduced new measures to empower innovation in drug and device pricing, aiming to support genuine innovation and improve the quality of healthcare in China [5][36]. Investment Recommendations - The report suggests focusing on high-quality stocks in the following segments: innovative drugs, CXO (Contract Research Organization), chain pharmacies, medical services, and second-class vaccines [5][37][38]. - Recommended stocks include Betta Pharmaceuticals, Teva Biopharmaceuticals, Kaili Medical, Haier Biomedical, Huaxia Eye Hospital, and Lao Bai Xing [5][38]. Stock Performance - During the last week, 337 stocks in the sector increased in value (71.10%), while 127 stocks decreased (26.79%). The top five gainers were Haitai Biological (46.93%), Zhendong Pharmaceutical (42.89%), Saili Medical (31.73%), Chenxin Pharmaceutical (30.75%), and Rendu Biological (27.82%) [4][27].

New Stock Issuance - Tianfu Long (732406) issued at a price of 23.60 on July 28, 2025[1] - Shenkai Co. (002633) has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17 to August 15, 2025[1] Abnormal Fluctuations - ST Wanfang (000638) reported significant abnormal fluctuations on July 25, 2025[2] - ST Zhengping (603843) experienced abnormal fluctuations on July 24, 2025[2] - Jiangnan Chemical (002226) noted abnormal fluctuations on July 23, 2025[2] Market Alerts - ST Zitian (300280) reported severe abnormal fluctuations on July 21, 2025[1] - Huayin Power (600744) indicated abnormal fluctuations on July 15, 2025[1] - ST Gaohong (000851) reported abnormal fluctuations on July 23, 2025[3]

证券代码：603367 证券简称：辰欣药业 公告编号：2025-034 辰欣药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 辰欣药业股份有限公司（以下简称"辰欣药业"或"公司"）于 2025 年 7 月 18 日、2025 年 7 月 21 日、2025 年 7 月 22 日连续三个交易日内日收盘价格 涨幅偏离值累计达到 20%，根据《上海证券交易所交易规则》的有关规定，属于 股票交易异常波动情形。 经公司自查，并向公司控股股东及实际控制人书面询证，截至本公告披 露日，公司不存在应披露而未披露的重大事项或重要信息。 公司敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 2、重大事项情况 经公司自查，并向公司控股股东及实际控制人书面征询核实：截至本公告披 露日，控股股东及实际控制人均不存在其他应披露而未披露的重大信息，包括但 不限于重大资产重组、股份发行、收购、债务重组、重大交易类事项、业务重组、 股份回购、股权激励、破产重整、重大业务合作、引进战略投资者、资产剥离 ...

Core Viewpoint - The announcement details the release of pledged shares by a major shareholder, Han Yanzhen, of Chenxin Pharmaceutical Co., Ltd, indicating a reduction in pledged shares and potential implications for shareholder confidence and company liquidity [1][2]. Shareholding Information - As of the announcement date, Han Yanzhen holds 31,977,829 shares, representing 7.06% of the company's total share capital [1]. - Han Yanzhen has released 7,920,000 shares from pledge, which accounts for 1.75% of the total share capital [1]. - After the release, Han Yanzhen has a total of 13,350,000 shares still pledged, which is 2.95% of the total share capital and 41.75% of his holdings [1]. Pledge Details - The release of the pledged shares was completed on June 27, 2025 [1]. - The released shares represent 24.77% of Han Yanzhen's total holdings [1]. - There are currently no plans for subsequent pledges of the released shares, and the company will fulfill its disclosure obligations as required by relevant laws and regulations if any new pledges occur in the future [1].

证券代码：603367 证券简称：辰欣药业 公告编号：2025-033 辰欣药业股份有限公司 | 股东名称 | 韩延振 | | --- | --- | | 本次解除质押股份 | 7,920,000 股 | | 占其所持股份比例 | 24.77% | | 占公司总股本比例 | 1.75% | | 解除质押时间 | 2025.6.27 | | 持股数量 | 31,977,829 股 | 1 关于持股 5%以上股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截止本公告日，辰欣药业股份有限公司（以下简称"公司）持股 5%以上股东韩 延振持有公司股份 31,977,829 股，占公司总股本比例为 7.06%。 韩延振本次解除质押股份 7,920,000 股，占公司总股本的 1.75%。本次股份解 除质押后，韩延振累计质押股份 13,350,000 股，占公司总股本的 2.95%，占其持股比 例的 41.75%。 公司于 2025 年 7 月 1 日收到持股 5%以上股东韩延振通知，告知其质押给 ...

Core Viewpoint - The announcement details the share pledge and release activities of major shareholder Han Yanzhen of Chenxin Pharmaceutical, indicating significant movements in shareholding and potential implications for the company's financial stability and investor confidence [1][2]. Shareholder Information - Han Yanzhen holds 31,977,829 shares, representing 7.06% of the total share capital of the company [1]. - After the release of 7,300,000 shares from pledge on June 20 and June 23, 2025, Han Yanzhen has 14,120,000 shares remaining pledged, which is 66.51% of his total holdings [1][2]. Pledge and Release Details - The total number of shares released from pledge is 7,300,000, accounting for 1.61% of the company's total share capital [1]. - The remaining pledged shares represent 3.12% of the company's total share capital [1]. Future Pledge Plans - On June 24, 2025, Han Yanzhen initiated a new pledge of shares, with the pledged amount being 7,150,000 shares, set to mature on June 24, 2026 [1]. - The new pledge represents 22.36% of Han Yanzhen's total holdings [1]. Cumulative Pledge Situation - The cumulative pledged shares by Han Yanzhen and his action-in-concert party, Nanjing Chenxin Tongtai Venture Capital Co., Ltd., total 33,346,115 shares, which is 7.36% of the company's total share capital [2].

证券代码：603367 证券简称：辰欣药业 公告编号：2025-032 辰欣药业股份有限公司 关于持股 5%以上股东部分股份解除质押及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截止本公告日，辰欣药业股份有限公司（以下简称"公司）持股 5%以上股东韩 延振持有公司股份 31,977,829 股，占公司总股本比例为 7.06%。韩延振将合计持有的 21,420,000 股股份办理了股票质押业务。本次解除质押及再质押后，韩延振累计质押 股份 21,270,000 股，占公司总股本的 4.70%，占其持股数量的比例为 66.51%。 2025 年 6 月 20 日及 2025 年 6 月 23 日，韩延振解除质押股份共计 7,300,000 股，占公司总股本的 1.61%。2025 年 6 月 24 日，韩延振将所持有的公司部分股份办理 了股票质押业务，根据股票质押式回购交易初始交易委托书，本次质押股份数量为 7,150,000 股。 公司于 2025 年 6 月 25 日收到持股 5%以上股东韩延 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2025-031 | 股东 | 是否为控 | 本次质押股 | 是否为 | 是否补 | 质押登记日 | 质押到期日 | 质权人 | 占其所 持股份 | 占公司 总股本 | 质押融 资资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | 数（股） | 限售股 | 充质押 | | | | | | | | | | | | | | | | 比例 | 比例 | 用途 | | | 否 | 6,200,000 | 否 | 否 | 2025.6.17 | 2026.6.17 | 中信证 | 19.39% | 1.37% | 偿还质 | | 韩延 | | | | | | | 券股份 | | | 押债务 | | 振 | | | | | | | 有限公 | | | （场内 | | | | | | | | | 司 | | | 或场外） | 1 | | | 辰欣药业股份有限公司 关于持股5%以上股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 ...